<- Go Home
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Market Cap
$991.0M
Volume
101.9K
Cash and Equivalents
$63.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$85.03
52 Week Low
$11.17
Dividend
N/A
Price / Book Value
24.00
Price / Earnings
-23.75
Price / Tangible Book Value
24.00
Enterprise Value
$943.4M
Enterprise Value / EBITDA
N/A
Operating Income
-$31.7M
Return on Equity
301.19%
Return on Assets
-47.54
Cash and Short Term Investments
$63.6M
Debt
$16.0M
Equity
$38.7M
Revenue
N/A
Unlevered FCF
-$13.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium